NEW YORK (GenomeWeb News) – SeqWright today said that it will be the exclusive genetic testing provider for Pharmagenoma's HairDx test, which evaluates a patient's responsiveness to hair-loss treatment finasteride.
Houston-based SeqWright runs a clinical lab that offers genetic testing. The firm also offers genomics services including next-generation sequencing.
SeqWright said that the test would enable patients to determine if treatment benefit outweighs the potential side effects associated with finasteride.
Terms of the agreement were not disclosed.